drugset / Trial / NCT02234297

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery

NCT02234297 ↗

Phase 1 Completed 17 enrolled Blaze Bioscience Inc.
NaSingle-groupOpen-label

Summary

Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. We hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as operate. This is a safety study to assess the safety of BLZ-100 in patients with gliomas undergoing surgery.

Timeline

Start
2014-10
Primary completion
2016-02
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject tozuleristide Diagnostic / imaging agent — Intravenous

Indications